Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: ...
Zacks Investment Research on MSN
Viatris gets FDA nod for generic Sandostatin, shares regulatory updates
Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements ...
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today the launch of the first and only generic ...
Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...
On Track To Initiate Pivotal Trial Of Octreolin TM (An Oral Form Of Octreotide Acetate) In Patients With Acromegaly By Year End 2010 NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a ...
Morristown, N.J. – April 28, 2014 – Capsugel today announced an agreement with Chiasma, Inc., wherein Capsugel's Dosage Form Solutions (DFS) business unit is scaling up manufacturing for the only ...
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. GlobeNewswire October 01, 2024 PARSIPPANY, N.J., Oct.
This first-to-market launch showcases Teva's proven strengths in complex generic formulations and enhances Teva's strategic goal of sustaining a generic powerhouse. Octreotide acetate for injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results